Howland Capital Management LLC Cuts Position in AstraZeneca PLC (NASDAQ:AZN)

Howland Capital Management LLC decreased its holdings in AstraZeneca PLC (NASDAQ:AZNFree Report) by 4.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 11,308 shares of the company’s stock after selling 500 shares during the quarter. Howland Capital Management LLC’s holdings in AstraZeneca were worth $762,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Fairfield Bush & CO. acquired a new stake in AstraZeneca in the first quarter valued at approximately $28,000. Panagora Asset Management Inc. grew its position in AstraZeneca by 55.1% in the first quarter. Panagora Asset Management Inc. now owns 11,956 shares of the company’s stock valued at $793,000 after acquiring an additional 4,249 shares in the last quarter. BlackRock Inc. grew its position in AstraZeneca by 22.0% in the first quarter. BlackRock Inc. now owns 7,466,492 shares of the company’s stock valued at $495,328,000 after acquiring an additional 1,343,939 shares in the last quarter. Great West Life Assurance Co. Can grew its position in AstraZeneca by 102.7% in the first quarter. Great West Life Assurance Co. Can now owns 525 shares of the company’s stock valued at $36,000 after acquiring an additional 266 shares in the last quarter. Finally, Moors & Cabot Inc. grew its position in AstraZeneca by 2.8% in the first quarter. Moors & Cabot Inc. now owns 10,841 shares of the company’s stock valued at $719,000 after acquiring an additional 292 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

AZN has been the subject of a number of recent analyst reports. Jefferies Financial Group downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. HSBC initiated coverage on shares of AstraZeneca in a research report on Monday, December 18th. They set a “buy” rating for the company. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Finally, Morgan Stanley began coverage on shares of AstraZeneca in a research report on Tuesday, January 23rd. They set an “overweight” rating for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, AstraZeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.00.

Check Out Our Latest Stock Analysis on AstraZeneca

AstraZeneca Stock Performance

AstraZeneca stock traded up $0.02 during mid-day trading on Wednesday, reaching $67.02. The company’s stock had a trading volume of 1,111,808 shares, compared to its average volume of 6,164,459. The firm has a market cap of $207.79 billion, a price-to-earnings ratio of 34.90, a PEG ratio of 1.24 and a beta of 0.50. The business has a 50 day moving average price of $65.69 and a 200-day moving average price of $65.80. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.57. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $76.56.

AstraZeneca (NASDAQ:AZNGet Free Report) last posted its earnings results on Thursday, February 8th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). The company had revenue of $12.02 billion during the quarter, compared to the consensus estimate of $12.07 billion. AstraZeneca had a net margin of 13.00% and a return on equity of 30.19%. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.69 earnings per share. Sell-side analysts predict that AstraZeneca PLC will post 4.01 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Monday, March 25th. Investors of record on Friday, February 23rd were paid a dividend of $0.965 per share. This is a boost from AstraZeneca’s previous Semi-Annual dividend of $0.47. This represents a dividend yield of 2.3%. The ex-dividend date was Thursday, February 22nd. AstraZeneca’s payout ratio is currently 100.52%.

AstraZeneca Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

See Also

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.